The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next generation of KRAS inhibitors.

Young cancer survivors are at increased risk for developing HPV-related malignancies, with female and male survivors at 1.4- to 2.5-fold excess risk, respectively, compared with the general population ...

Vaccine R&D has been revitalized recently in part owing to major commercial successes and increased incentives for products that address neglected diseases. Our interviewees this month describe ...

Gardasil is a vaccine, licensed for use in June 2006, by the FDA. It targets four strains of human papillomavirus (HPV ... How long is Gardasil effective? Research suggests the vaccine lasts ...

This collection aims to gather the state of the art of therapeutic HPV vaccine research – from novel vaccine design concepts, to preclinical models, to results of clinical trials. This ...

One dose of a human papillomavirus (HPV ... vaccine efficacy that exceeded 97%, reported Aimée Kreimer, PhD, of the National Cancer Institute, at the American Association for Cancer Research ...

HPV, short for human papillomavirus, is a common, sexually transmitted infection. The vaccine to prevent it has been around for almost 20 years now. Recent research from the Fred Hutchinson Cancer ...